The science is clearer
when it has a story.

Imagine a world where diagnosing a broken bone depended largely on educated guesswork, where looking inside the human body was a medical fantasy, and where the inner structure of atoms remained a complete mystery. X-ray imaging feels indispensable today, but it emerged only recently from centuries of curiosity, unexpected observations and persistent experimentation.

The story begins in the public marketplaces and fairs of seventeenth-century Europe. Demonstrations of static electricity made sparks leap from fingertips, caused hair to stand on end and moved lightweight objects without visible contact. What seemed like magic gradually became a subject of serious scientific inquiry.

Around 1745, Pieter van Musschenbroek and Ewald Georg von Kleist independently developed the Leyden jar. With metal foil inside and outside a glass vessel, it could store static electrical charge. This primitive capacitor made electricity available for repeatable experiments, even as public showmen continued to use it for spectacular—and sometimes painful—demonstrations.

A decisive change came in 1800 when Alessandro Volta created the voltaic pile, the first true battery. Electricity was no longer limited to a single spark. A steady current allowed scientists to perform longer and more controlled experiments. Humphry Davy used it for electrolysis and discovered elements including potassium and sodium. Michael Faraday then revealed deep connections among electricity, magnetism and chemistry.

Scientists also began studying what happened when electricity passed through gases. Davy’s arc lamp showed that a strong current could ionise air and create intense light, but researchers needed enclosed spaces where pressure and gas composition could be controlled.

Heinrich Geissler’s mercury vacuum pump, developed in 1855, made that possible. Electricity passing through low-pressure gases in Geissler tubes produced striking coloured glows—the ancestors of modern neon lighting. In the late 1870s, William Crookes used stronger vacuums and observed mysterious cathode rays streaming from the negative electrode. They cast shadows and responded to magnets, fuelling debate over whether they were light or charged particles.

Several researchers came close to the next discovery. Philipp Lenard modified the Crookes tube with a thin aluminium window and observed effects outside it. Other laboratories saw photographic plates fog unexpectedly or fluorescent materials glow, but these clues were often dismissed as experimental errors. The evidence was present before its meaning was recognised.

On 8 November 1895, Wilhelm Roentgen was experimenting with a covered Crookes tube in a darkened room at the University of Würzburg. A nearby screen coated with barium platinocyanide began to glow even though visible light from the tube could not reach it. Roentgen tested books, wood, metal and eventually his own hand. The unknown radiation passed through soft tissue but left the bones as shadows.

Roentgen investigated for weeks before publishing “On a New Kind of Rays.” On 22 December, he made the famous radiograph of his wife Bertha’s hand, with her bones and wedding ring clearly visible. The image was unsettling and revolutionary: medicine could now look inside a living body without an incision.

The discovery spread rapidly. Within months, hospitals were using X-rays to find fractures and foreign bodies. Roentgen’s work also prompted Henri Becquerel to investigate whether fluorescent minerals emitted similar rays. Becquerel’s observation that uranium salts exposed photographic plates without sunlight led to the discovery of radioactivity. Marie and Pierre Curie then identified polonium and radium, opening an entirely new chapter in physics and medicine.

X-rays did not emerge from a single isolated flash of genius. They were the culmination of a long chain: stored static charge, continuous current, electromagnetism, gas discharges, vacuum technology and cathode-ray experiments. Each step created the conditions for the next, until an unfamiliar glow was finally recognised for what it could reveal.

The discovery of X-rays in 1895 immediately revealed the invisible. It also revealed danger. Prolonged exposure caused skin redness, burns and tissue damage. Yet those same biological effects suggested that this new form of energy might be used therapeutically.

One of the earliest pioneers was the Viennese dermatologist Léopold Freund. In 1896, he used X-rays to treat a young girl with a large hairy birthmark, successfully removing the excessive hair. That same year in Chicago, medical student Emil Grubbe used X-rays in an attempt to treat recurrent breast cancer. These treatments were crude by modern standards, but they marked an important conceptual leap: radiation could do more than create an image.

Early machines were inconsistent, making the delivered dose difficult to control. A major improvement arrived in 1913 with William D. Coolidge’s hot-cathode X-ray tube. Unlike earlier gas-filled tubes, it produced a stable, high-intensity beam whose output could be controlled more reliably. The Coolidge tube became a foundation of radiology and early radiation treatment.

The biological cost of progress was severe. Radiation burns, tissue necrosis and cancers appeared among patients and practitioners, including some of the field’s pioneers. Their injuries made the need for dose measurement, shielding and safety protocols impossible to ignore.

Radium offered another route. Discovered by Marie and Pierre Curie in 1898, it emitted radiation continuously without an external power source. By the early twentieth century, physicians were placing small radium sources inside or near tumours. This approach—brachytherapy—could deliver a high dose locally while limiting exposure to more distant healthy tissue.

Radium was powerful but hazardous. Radiation safety was still poorly understood, and both patients and staff could be overexposed. Marie Curie’s eventual death from aplastic anaemia, likely related to prolonged radiation exposure, became part of the sobering legacy that shaped safer practice.

The 1950s brought Cobalt-60 teletherapy. Artificially produced Cobalt-60 emitted gamma rays energetic enough to treat deeper tumours. Its greater penetration and skin-sparing properties helped launch the megavoltage era, moving radiotherapy beyond the limitations of lower-energy orthovoltage machines.

At roughly the same time, the medical linear accelerator emerged. Linacs use high-frequency electromagnetic waves to accelerate electrons. The electrons can treat superficial tumours directly or strike a metal target to create high-energy X-rays for deep disease. Magnetron technology, developed for radar during the Second World War, supplied the microwaves that made this acceleration possible.

Imaging then transformed planning. CT in the 1970s and MRI in the 1980s allowed tumours and organs to be visualised in three dimensions. Radiation fields could be designed around the individual patient rather than inferred from surface landmarks and two-dimensional images.

By the 1990s and early 2000s, intensity-modulated radiation therapy shaped dose around complex tumour geometry, while image-guided radiation therapy checked anatomy during treatment. Particle therapy added another physical advantage: protons release most of their energy at a selected depth through the Bragg peak, reducing dose beyond the target—particularly valuable near critical structures and in children.

Radiotherapy evolved because clinicians and scientists repeatedly converted danger into understanding and instability into control. What began as an uncontrolled physical curiosity became a therapeutic discipline built on measurement, imaging, radiobiology and precision.

Modern radiation therapy is defined by precision, but that precision was built incrementally. Many of its advances originated outside oncology—in nuclear physics, radar, computing and medical imaging—before being adapted to the problem of treating cancer while protecting normal tissue.

Cobalt-60 machines, introduced in the 1950s, emitted gamma rays of approximately 1.25 million electron volts. Compared with earlier X-ray equipment, they offered better penetration and a useful skin-sparing effect. A substantial dose could reach tumours many centimetres beneath the surface, making treatment of deeper disease more practical.

Cobalt-60 also had limitations. Its energy was still inadequate for some very deep targets, and the radioactive source decayed continuously. Sources required periodic replacement, creating technical, logistical and environmental challenges.

The medical linear accelerator addressed many of these problems. In 1953, Hammersmith Hospital in London became one of the first centres to use a linac clinically, treating a patient with retinoblastoma. Linacs accelerated electrons through a linear tube using high-frequency electromagnetic waves. Electrons could treat superficial disease directly, or generate high-energy X-rays when directed onto a metal target.

Linacs provided higher energies, improved penetration and avoided a continuously radioactive source. By the 1970s, machines could produce several photon and electron energies, giving clinicians far greater flexibility in matching the beam to the depth and geometry of disease.

Radiation delivery improved, but the next revolution came from seeing anatomy in three dimensions. CT planning allowed oncologists to localise tumours and normal organs throughout the patient’s volume. Three-dimensional conformal radiation therapy then used computer-designed beam shapes to surround the tumour more closely and reduce unnecessary dose.

Intensity-modulated radiation therapy extended this principle by varying the intensity within each field. Optimisation algorithms could sculpt complex dose distributions around sensitive structures while maintaining target coverage. Image-guided radiation therapy added imaging at the treatment machine, allowing clinicians to account for setup variation, breathing, organ motion and anatomical change.

Stereotactic radiosurgery and stereotactic body radiation therapy pushed accuracy further, delivering very high doses in one or a few sessions with sub-millimetre precision. Techniques first developed for intracranial targets expanded to tumours in the lung, liver, spine and other sites, sometimes achieving outcomes comparable with surgery in carefully selected patients.

Proton therapy uses a different physical interaction. Protons deposit most of their energy near a selected depth—the Bragg peak—with relatively little exit dose. This can reduce exposure to healthy tissue, especially in children and when tumours lie close to critical structures.

Artificial intelligence is now entering contouring, planning and adaptive workflows. Algorithms can automate the delineation of tumours and organs, optimise dose and help revise plans as anatomy changes. The opportunity is substantial, although the profession must preserve the clinical judgment needed to supervise these systems and recognise their errors.

MR-linacs combine a linear accelerator with MRI. Real-time soft-tissue visualisation during treatment can support dynamic targeting and online adaptation beyond what is possible with conventional cone-beam CT. The treatment machine is becoming not merely a radiation source, but an integrated platform for imaging, decision-making and delivery.

The arc from Cobalt-60 to MR-guided adaptive therapy is more than a sequence of machines. It is a history of progressively tighter feedback between what we can see, what we can calculate and what we can safely deliver. That convergence has improved tumour control, reduced toxicity and changed what is possible for patients.

Loading article…